Biomarkers in Parkinsonian Syndromes

Launched by NON-PROFIT ORGANIZATION FOR SCIENTIFIC RESEARCH IN PARKINSON'S DISEASE AND RELATED DISORDERS · Jul 8, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Biomarkers in Parkinsonian Syndromes," aims to understand the early signs and changes in patients with different types of parkinsonian disorders, such as Parkinson's disease and Progressive Supranuclear Palsy. Researchers will track patients who have recently started showing symptoms of these conditions for at least five years. They will collect various types of information, including brain scans and other biological markers, to help identify patterns that could lead to better diagnosis and treatment in the future.

To be eligible for the study, participants need to provide written consent and can include patients who have had symptoms for less than two years or more than two years, as well as healthy individuals without any neurological issues. However, those with certain conditions, like drug-induced parkinsonism or specific brain abnormalities, will not qualify. If you choose to participate, you can expect regular check-ups and tests to help researchers gather valuable information about these disorders. This study is currently recruiting participants of all ages and genders.

Gender

ALL

Eligibility criteria

• IΙnclusion Criteria:
• • Written informed consent, including consent to monitoring
• • Patients with Parkinsonism and disease duration \< 2 years
• • Patients with Parkinsonism and disease duration \> 2 years
• • Healthy individuals without any neurological disease
• Exclusion Criteria:
• • Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide).
• • Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism).
• • Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm
• • Other serious diseases that indicate a life expectancy of \<5 years.
• • Active participation in other interventional clinical studies